JAMES TOLENTINO: Open Payments
NPI 1972131761 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,507 in 279 payments from 21 companies in 2025. Trend: 2023 $5,483 · 2024 $6,079 · 2025 $6,507
Food & beverage: $6,507
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $1,011 |
| Janssen Pharmaceuticals, Inc | 30 | $989 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $666 |
| Teva Pharmaceuticals USA, Inc. | 37 | $664 |
| Neurocrine BioSciences, Inc. | 17 | $545 |
| Vanda Pharmaceuticals Inc. | 23 | $520 |
| Lundbeck LLC | 18 | $381 |
| Alkermes, Inc. | 10 | $351 |
| Otsuka America Pharmaceutical, Inc. | 12 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $167 |
Products named: VRAYLAR, SPRAVATO, CAPLYTA, INGREZZA, REXULTI, FANAPT, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
